Aclidinium bromide inhibits the growth and metastasis of gastric cancer MKN ‑28 cells via the PI3K signaling pathway.
In conclusion, aclidinium bromide could inhibit gastric cancer cell proliferation and metastasis, which may be associated with the enhancement of apoptosis induced by the PI3K signaling pathway.
PMID: 29956761 [PubMed - as supplied by publisher] (Source: Molecular Medicine Reports)
Source: Molecular Medicine Reports - July 1, 2018 Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Aclidinium bromide inhibits proliferation, migration and invasion but promotes apoptosis of human glioma cells via PI3K/AKT signaling pathway.
Abstract
The aim of the study was to investigate the anticancer potential of Aclidinium bromide (INN) in glioblastoma. Glioblastoma cell lines U251 and U87 were treated with INN. The effects of INN on cell migration and invasion were assessed by transwell migration and invasion assays. Additionally, the effects of INN on the proliferation and apoptosis were detected by CCK-8 kit and flow cytometry. Western blotting was employed to determine anti-apoptotic proteins and the signaling pathway changes. The results showed that INN effectively suppressed proliferation, migration and invasion and induced apoptosi...
Source: Neoplasma - June 26, 2018 Category: Cancer & Oncology Authors: Huang SH, Zhang T, Zhao CG, Qin J, Qi P, Li FT, He XJ Tags: Neoplasma Source Type: research
Role of budesonide, formoterol fumarate and aclidinium bromide in the inflammaging of airway epithelial cells
Conclusions: These findings suggest a new effect of combination with BUD, ACL and FO in counteracting inflammaging processes induced by cigarette smoke exposure. (Source: European Respiratory Journal)
Source: European Respiratory Journal - December 6, 2017 Category: Respiratory Medicine Authors: Pace, E., Di Vincenzo, S., Ferraro, M., Dino, P., Gjomarkaj, M. Tags: Airway Cell Biology and Immunopathology Source Type: research
Aclidinium bromide improves symptoms and sleep quality in COPD: a pilot study
In patients with chronic obstructive pulmonary disease (COPD), nighttime and early-morning symptoms are associated with an increased rate of exacerbation, hospital admission and reduced survival [1, 2]. Furthermore, patients with COPD frequently have poor sleep quality [3] and reduced physical activity [4, 5]. We hypothesised that nighttime airflow obstruction in patients with COPD is associated with impaired sleep quality, leading to early-morning symptoms and reduced physical activity. (Source: European Respiratory Journal)
Source: European Respiratory Journal - June 22, 2017 Category: Respiratory Medicine Authors: Magnussen, H., Arzt, M., Andreas, S., Plate, T., Ribera, A., Seoane, B., Watz, H., Kirsten, A.-M. Tags: COPD and smoking Original Articles: Research letters Source Type: research
A randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease
Aclidinium bromide/formoterol fumarate (AB/FF) 400/12 μg efficacy and safety was demonstrated in two 6-month Phase III studies (AUGMENT and ACLIFORM) and a 12-month study in patients with moderate to severe chronic obstructive pulmonary disease (COPD). This Phase III, double-blind, placebo-controlled, 6-month AUGMENT extension investigated the long- term safety and tolerability of AB/FF 400/12 μg (NCT01572792). (Source: Respiratory Medicine)
Source: Respiratory Medicine - February 14, 2017 Category: Respiratory Medicine Authors: Anthony D'Urzo, Stephen Rennard, Edward Kerwin, James F. Donohue, Alejhandra Lei, Eduard Molins, Anne Leselbaum Source Type: research
Long Acting Muscarinic Antagonists for the Treatment of Chronic Obstructive Pulmonary Disease: A Review of Current and Developing Drugs.
This article reviews the clinical efficacy and adverse effects of currently available LAMAs in COPD treatment as well as developing LAMAs in early clinical trials and preclinical studies (V0162, TD-4208, CHF 5407, AZD9164, AZD8683, bencycloquidium). In addition, a new class of molecule that combines muscarinic antagonist and β2-adrenergic properties (MABA) is described and current developmental progress discussed (GSK-961081, THRX-200495). Expert Opinion: Future key areas for developing drugs for the management of COPD include prolonged duration of action, optimal delivery systems, synergistic combinations with other drug...
Source: Expert Opinion on Investigational Drugs - December 24, 2016 Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research
The effect of aclidinium bromide 400 {micro}g on sleep quality in COPD: A pilot study
Conclusions: In this pilot study, aclidinium 400 µg BID significantly improved lung function. Improvements were also observed in sleep quality, physical activity and symptoms in patients with moderate COPD. These changes may be clinically important and therefore require confirmation in adequately powered studies. (Source: European Respiratory Journal)
Source: European Respiratory Journal - November 7, 2016 Category: Respiratory Medicine Authors: Magnussen, H., Arzt, M., Andreas, S., Plate, T., Ribera, A., Seoane, B., Watz, H., Kirsten, A.-M. Tags: 5.1 Airway Pharmacology and Treatment Source Type: research
Reduction in clinically important deterioration in COPD with aclidinium/formoterol
Conclusion AB/FF 400/12 µg twice daily reduced the risk of first CID vs PBO, AB and FF, and also reduced sustained events vs PBO and FF. (Source: European Respiratory Journal)
Source: European Respiratory Journal - November 7, 2016 Category: Respiratory Medicine Authors: Singh, D., D'Urzo, A. D., Chuecos, F., Munoz, A., Garcia Gil, E. Tags: 5.1 Airway Pharmacology and Treatment Source Type: research
Evaluation of COPD Treatments: A Multicriteria Decision Analysis of Aclidinium and Tiotropium in the United States
Comparisons of the use of aclidinium bromide and tiotropium bromide for the treatment of chronic obstructive pulmonary disease often concentrate on key end points (exacerbations) at the expense of other benefits and risks. Multicriteria decision analysis (MCDA) can help overcome this by using stakeholder preferences to combine multiple end points into an overall value estimate. (Source: Value in Health)
Source: Value in Health - October 4, 2016 Category: Global & Universal Authors: Kevin Marsh, Erica Zaiser, Panagiotis Orfanos, Suzanne Salverda, Teresa Wilcox, Shawn Sun, Shailja Dixit Source Type: research
Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study
The efficacy and safety of twice-daily aclidinium bromide/formoterol fumarate was compared with that of salmeterol/fluticasone propionate in patients with stable, moderate-to-severe chronic obstructive pulmonary disease (COPD).
AFFIRM COPD (Aclidinium and Formoterol Findings in Respiratory Medicine COPD) was a 24-week, double-blind, double-dummy, active-controlled study. Patients were randomised (1:1) to aclidinium/formoterol 400/12 µg twice-daily via Genuair/Pressair or salmeterol/fluticasone 50/500 µg twice-daily via Accuhaler. The primary end-point was peak forced expiratory volume in 1 s (FEV...
Source: European Respiratory Journal - September 29, 2016 Category: Respiratory Medicine Authors: Vogelmeier, C., Paggiaro, P. L., Dorca, J., Sliwinski, P., Mallet, M., Kirsten, A.-M., Beier, J., Seoane, B., Segarra, R. M., Leselbaum, A. Tags: COPD and smoking Original Articles: COPD Source Type: research
The effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) diary: pooled analysis of two 6-month Phase III studies
Reducing the severity of respiratory symptoms is a key goal in the treatment of chronic obstructive pulmonary disease (COPD). We evaluated the effect of aclidinium bromide 400 μg twice daily (BID) on respirato... (Source: Respiratory Research)
Source: Respiratory Research - May 23, 2016 Category: Respiratory Medicine Authors: Paul W. Jones, Nancy K. Leidy, Asha Hareendran, Rosa Lamarca, Ferran Chuecos and Esther Garcia Gil Source Type: research
Effect of Aclidinium Bromide on Exacerbations in Patients with Moderate-to-Severe COPD: A Pooled Analysis of Five Phase III, Randomized, Placebo-Controlled Studies.
Authors: Wedzicha JA, Agusti A, Donaldson G, Chuecos F, Lamarca R, Gil EG
Abstract
We investigated the effect of the long-acting muscarinic antagonist aclidinium bromide on chronic obstructive pulmonary disease (COPD) exacerbations by pooling data from five randomized, placebo-controlled, parallel-group Phase III studies of 3-6 months' duration. Data were pooled from the aclidinium 400 μg twice-daily (BID) and placebo arms (N = 2,521) and stratified by Global initiative for chronic Obstructive Lung Disease (GOLD) group (A, B, C and D). Results showed that fewer patients experienced ≥1 exacerbation...
Source: COPD: Journal of Chronic Obstructive Pulmonary Disease - May 11, 2016 Category: Respiratory Medicine Tags: COPD Source Type: research
Long-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: Results of a randomized 1-year trial in patients with COPD
This was a one-year, Phase III randomized, double-blind, parallel-group active-control study investigating the long-term safety and tolerability of a twice-daily aclidinium 400 μg/formoterol 12 μg versus formoterol 12 μg. (Source: Respiratory Medicine CME)
Source: Respiratory Medicine CME - May 6, 2016 Category: Respiratory Medicine Authors: James F. Donohue, Weily Soong, Xiao Wu, Pomy Shrestha, Alejhandra Lei Source Type: research
Aclidinium bromide inhalation powder for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease including chronic bronchitis and emphysema.
Authors: Matera MG, Sanduzzi A, Alfano R, Cazzola M
Abstract
Aclidinium is a twice-daily long-acting muscarinic receptor antagonist (LAMA) with an interesting pharmacological profile. Recent evidence indicates that this LAMA, in addition to causing a significant improvement in lung function and other important supportive outcomes, such as health related quality of life, dyspnea and nighttime/early morning symptoms in patients suffering from COPD, is also able to significantly reduce the rate of exacerbations of any severity, is extremely effective in controlling the COPD symptoms, is able to reduce lung hy...
Source: Expert Review of Clinical Pharmacology - March 23, 2016 Category: Drugs & Pharmacology Tags: Expert Rev Clin Pharmacol Source Type: research
Efficacy and Safety of an Aclidinium Bromide Treatment for 12 Weeks or Longer in Patients with Moderate-To-Severe COPD: A Meta-Analysis.
CONCLUSIONS: Aclidinium reduced the incidence of exacerbation-related hospitalizations and improved quality of life, COPD symptoms and pulmonary function. In addition, aclidinium did not increase the incidence of non-fatal serious adverse events, cardiac adverse events, or COPD exacerbations and was not associated with increased mortality.
PMID: 26846588 [PubMed - as supplied by publisher] (Source: COPD: Journal of Chronic Obstructive Pulmonary Disease)
Source: COPD: Journal of Chronic Obstructive Pulmonary Disease - February 18, 2016 Category: Respiratory Medicine Tags: COPD Source Type: research
